Clearing the air: Uniquely engaging furin as an approach to cystic fibrosis therapy

Digant Nayak; Elizabeth V Wasmuth; Shaun K Olsen

doi:10.1016/j.chembiol.2022.05.011

Clearing the air: Uniquely engaging furin as an approach to cystic fibrosis therapy

Cell Chem Biol. 2022 Jun 16;29(6):927-929. doi: 10.1016/j.chembiol.2022.05.011.

Authors

Digant Nayak¹, Elizabeth V Wasmuth¹, Shaun K Olsen²

Affiliations

¹ Department of Biochemistry & Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
² Department of Biochemistry & Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. Electronic address: olsens@uthscsa.edu.

Abstract

In this issue of Cell Chemical Biology, Douglas et al. describe a potent, specific, and cell-permeable furin inhibitor that interacts with a cryptic binding site to rescue hallmarks of cystic fibrosis in human ex vivo models. BOS-318 holds promise for development of therapeutics targeting an array of furin-dependent pathologies.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Comment

MeSH terms

Binding Sites
Cystic Fibrosis* / drug therapy
Cystic Fibrosis* / metabolism
Furin* / chemistry
Furin* / metabolism
Humans
Protein Domains

Substances

Furin

Abstract

Publication types

MeSH terms

Substances

Grants and funding